A New Approach to Deliver Anti-cancer Nanodrugs with Reduced Off-target Toxicities and Improved Efficiency by Temporarily Blunting the Reticuloendothelial System with Intralipid

We have developed a new strategy to temporarily blunt the reticuloendothelial system uptake of nanodrugs, a major challenge for nanodrug delivery and causing off-target toxicities, using an FDA approved nutrition supplement, Intralipid. We have tested our methodology in rats using an experimental pl...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2017-11, Vol.7 (1), p.16106-13, Article 16106
Main Authors: Liu, Li, Ye, Qing, Lu, Maggie, Chen, Shih-Ta, Tseng, Hsiang-Wen, Lo, Ya-Chin, Ho, Chien
Format: Article
Language:English
Subjects:
13/51
631/154/152
631/154/570
631/67/1059
Bioavailability
Cancer
Humanities and Social Sciences
Kidneys
Liver
multidisciplinary
Platinum
Reticuloendothelial system
Rodents
Science
Science (multidisciplinary)
Spleen
Xenografts
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We have developed a new strategy to temporarily blunt the reticuloendothelial system uptake of nanodrugs, a major challenge for nanodrug delivery and causing off-target toxicities, using an FDA approved nutrition supplement, Intralipid. We have tested our methodology in rats using an experimental platinum-containing anti-cancer nanodrug and three FDA approved nanodrugs, Abraxane, Marqibo, and Onivyde, to determine their toxicities in liver, spleen, and kidney, with and without the addition of Intralipid. Our method illustrates its potentials to deliver nanodrugs with an increase in the bioavailability and a decrease in toxicities. Our study shows that Intralipid treatment exhibits no harmful effect on tumor growing and no negative effect on the anti-tumor efficacy of the platinum-containing nanodrug, as well as animal survival rate in a HT-29 xenograft mouse model. Our methodology could also be a valuable complement/supplement to the “stealth” strategies. Our approach is a general one applicable to any approved and in-development nanodrugs without additional modification of the nanodrugs, thus facilitating its translation to clinical settings.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-017-16293-6